康希諾/聯邦制藥/威高股份急漲10%-12% 後者再創紀錄高
本月初獲野村升價至21.9元及重申「買入」的威高股份(01066.HK)反覆探頂,今天股價突破上周五所創紀錄高位20.25元,最高見21.6元,現造21.25元,續漲12%,成交已較昨天全日高近八成至3,327萬股,涉資6.95億元。
全球三種領先候選新冠肺炎疫苗公布積極進展,其中軍事科學院與康希諾生物(06185.HK)研發疫苗在列。此外,美國總統特朗普聲稱願意與中國或其他國家合作,將有效新冠病毒疫苗帶到美國。
康希諾股價三連漲,今天重越20天及10天線(222.08元及225.64元),最高238元,現造233元,續漲逾10%,成交額5.96億元。此外,上月下旬遭控股東以每股7.24元配售公司1.08億股的聯邦制藥(03933.HK)升破20天、10天及50天線(7-7.2元),最高見7.82元,現造7.76元,急彈11%,成交增至1,945萬股,涉資1.459億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.